{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:29Z","timestamp":1790352149564,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T00:00:00Z","timestamp":1688774400000},"content-version":"am","delay-in-days":494,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-AG047036"],"award-info":[{"award-number":["R21-AG047036"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K24-DK091419"],"award-info":[{"award-number":["K24-DK091419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK078106"],"award-info":[{"award-number":["R01-DK078106"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01-DK096920"],"award-info":[{"award-number":["R01-DK096920"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01-DK102163"],"award-info":[{"award-number":["U01-DK102163"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1053\/j.ackd.2021.11.006","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T19:31:48Z","timestamp":1657308708000},"page":"149-160.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Thrombotic Microangiopathy Syndromes\u2014Common Ground and Distinct Frontiers"],"prefix":"10.1053","volume":"29","author":[{"given":"Ramy M.","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kammi","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoney","family":"Ferrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-3772","authenticated-orcid":false,"given":"Richard","family":"Burwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNH.0000000000000499","article-title":"Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition","volume":"28","author":"Hanna","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib2","doi-asserted-by":"crossref","DOI":"10.5301\/jo-n.5000021","article-title":"Thrombotic microangiopathy due to Catastrophic antiphospholipid antibody syndrome confirmed on skin biopsy and treated with eculizumab","volume":"1","author":"Hanna","year":"2017","journal-title":"J Onco Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000512227","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report","volume":"11","author":"Torres","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib4","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1177\/0300060519864808","article-title":"Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy","volume":"47","author":"Hanna","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1053\/j.ackd.2021.11.006_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12959-019-0207-7","article-title":"Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease","volume":"17","author":"Hanna","year":"2019","journal-title":"Thromb J"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transpl"},{"key":"10.1053\/j.ackd.2021.11.006_bib7","series-title":"Complement Targeting Therapies for Refractory C3 Glomerulopathy [Abstract]","author":"Chancillini","year":"2014"},{"issue":"21","key":"10.1053\/j.ackd.2021.11.006_bib8","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ackd.2021.11.006_bib9","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib11","doi-asserted-by":"crossref","first-page":"e6056","DOI":"10.1097\/MD.0000000000006056","article-title":"Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: a case report","volume":"96","author":"Abe","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2021.11.006_bib12","first-page":"4325647","article-title":"Severe vitamin B12 deficiency in pregnancy Mimicking HELLP syndrome","volume":"2019","author":"Govindappagari","year":"2019","journal-title":"Case Rep Obstet Gynecol"},{"key":"10.1053\/j.ackd.2021.11.006_bib13","article-title":"Finding of pathological thrombomodulin gene variant in a patient with idiopathic nodular glomerulosclerosis and chronic thrombotic microangiopathy-like changes","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An Ex\u00a0vivo test of complement activation on endothelium for Individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"23","key":"10.1053\/j.ackd.2021.11.006_bib15","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol"},{"key":"10.1053\/j.ackd.2021.11.006_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fmed.2020.00293","article-title":"Diverse clinical presentations of C3 Dominant glomerulonephritis","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib18","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.4081\/hr.2016.6625","article-title":"Atypical hemolytic uremic syndrome secondary to lupus nephritis, sensitive to eculizumab","volume":"8","author":"Raufi","year":"2016","journal-title":"Hematol Rep"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-148-8-200804150-00003","article-title":"Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia","volume":"148","author":"Brodsky","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2021.11.006_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2015.1.385","article-title":"Complement in hemolytic anemia","volume":"2015","author":"Brodsky","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1053\/j.ackd.2021.11.006_bib21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2021.11.006_bib22","series-title":"GeneReviews\u00ae","article-title":"Genetic atypical hemolytic-uremic syndrome","author":"Noris","year":"1993"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib23","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","article-title":"Overview of complement activation and regulation","volume":"33","author":"Noris","year":"2013","journal-title":"Semin Nephrol"},{"issue":"21","key":"10.1053\/j.ackd.2021.11.006_bib24","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1182\/blood-2016-11-743104","article-title":"None of the above: thrombotic microangiopathy beyond TTP and HUS","volume":"129","author":"Masias","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","article-title":"Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence","volume":"96","author":"Hanna","year":"2019","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ckj\/sfy060","article-title":"Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension","volume":"12","author":"Hanna","year":"2019","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13730-020-00504-7","article-title":"Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer","volume":"10","author":"Morimoto","year":"2021","journal-title":"CEN Case Rep"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/his.13716","article-title":"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy","volume":"73","author":"Pfister","year":"2018","journal-title":"Histopathology"},{"issue":"4","key":"10.1053\/j.ackd.2021.11.006_bib30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bjh.12387","article-title":"Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up","volume":"162","author":"Tsai","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2018.03.005","article-title":"Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies","volume":"57","author":"Vigna","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/jth.13922","article-title":"An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura","volume":"16","author":"Roose","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib34","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1055\/s-0037-1615252","article-title":"Anti-ADAMTS13 antibodies and a novel Heterozygous p.R1177Q mutation in a case of pregnancy-Onset immune-mediated thrombotic thrombocytopenic purpura","volume":"2","author":"Roose","year":"2018","journal-title":"TH Open"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/17474086.2016.1122515","article-title":"ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies","volume":"9","author":"Tersteeg","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.ackd.2021.11.006_bib36","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1053\/j.ackd.2021.11.006_bib37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17474086.2020.1819230","article-title":"A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Gomez-Segui","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.transci.2018.01.003","article-title":"Cobalamin deficiency presenting with thrombotic microangiopathy (TMA) features: a systematic review","volume":"57","author":"Tran","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1053\/j.ackd.2021.11.006_bib39","first-page":"127","article-title":"Vitamin B12 deficiency presenting as pseudo-thrombotic microangiopathy: a case report and literature review","volume":"11","author":"Fahmawi","year":"2019","journal-title":"Clin Pharmacol"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ped.12953","article-title":"Cobalamin C defect-hemolytic uremic syndrome caused by new mutation in MMACHC","volume":"58","author":"Adrovic","year":"2016","journal-title":"Pediatr Int"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib42","doi-asserted-by":"crossref","DOI":"10.21767\/2472-5056.100011","article-title":"Typical Hus: evidence of acute phase complement activation from a Daycare Outbreak","volume":"1","author":"Brady","year":"2016","journal-title":"J Clin Exp Nephrol"},{"issue":"21","key":"10.1053\/j.ackd.2021.11.006_bib43","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib44","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00467-018-3972-9","article-title":"Eculizumab in STEC-HUS: need for a proper randomized controlled trial","volume":"33","author":"Loos","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2021.11.006_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-018-0168-2","article-title":"Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy","volume":"16","author":"Wada","year":"2018","journal-title":"Thromb J"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40560-014-0061-4","article-title":"Complement, thrombotic microangiopathy and disseminated intravascular coagulation","volume":"2","author":"Kurosawa","year":"2014","journal-title":"J Intensive Care"},{"issue":"4","key":"10.1053\/j.ackd.2021.11.006_bib47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement mediated thrombotic microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am J Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2021.11.006_bib49","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000002291","article-title":"Belatacept in solid organ transplant: review of current literature across transplant types","volume":"102","author":"Perez","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib50","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","article-title":"Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report","volume":"11","author":"Facchini","year":"2017","journal-title":"J Med Case Rep"},{"issue":"12","key":"10.1053\/j.ackd.2021.11.006_bib52","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/ccr3.1214","article-title":"Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment","volume":"5","author":"Gosain","year":"2017","journal-title":"Clin Case Rep"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.V128.22.136.136","article-title":"Efficacy of eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"128","author":"Grall","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ackd.2021.11.006_bib55","first-page":"7063145","article-title":"Drug-induced thrombotic microangiopathy due to Cumulative toxicity of Ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep Hematol"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13730-018-0332-3","article-title":"Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome","volume":"7","author":"Katagiri","year":"2018","journal-title":"CEN Case Rep"},{"issue":"10","key":"10.1053\/j.ackd.2021.11.006_bib58","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1016\/j.transproceed.2018.07.020","article-title":"Development of focal segmental glomerulosclerosis and thrombotic microangiopathy in a liver transplant patient on Sorafenib for Hepatocellular Carcinoma: a case report","volume":"50","author":"Hanna","year":"2018","journal-title":"Transpl Proc"},{"issue":"24","key":"10.1053\/j.ackd.2021.11.006_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MD.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2021.11.006_bib60","doi-asserted-by":"crossref","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","article-title":"Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal Use","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1053\/j.ackd.2021.11.006_bib61","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ekir.2019.07.019","article-title":"Development of collapsing focal and segmental glomerulosclerosis after receiving intravitreal vascular endothelial growth factor blockade","volume":"4","author":"Nobakht","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib62","first-page":"10","article-title":"Eculizumab refractory thrombotic thrombocytopenic purpura secondary to post-endoscopic retrograde cholangiopancreatography pancreatitis in a patient","volume":"6","author":"Malik","year":"2016","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib63","first-page":"478","article-title":"Secondary thrombotic microangiopathy and eculizumab: a reasonable therapeutic option","volume":"37","author":"Roman","year":"2017","journal-title":"Nefrologia"},{"issue":"23","key":"10.1053\/j.ackd.2021.11.006_bib64","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-Arm, open-Label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2021.11.006_bib66","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2019.02166","article-title":"Complement inhibitors in clinical trials for glomerular diseases","volume":"10","author":"Zipfel","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mayocpiqo.2017.11.004","article-title":"Complement regulatory genetic mutations in the setting of autoimmune thrombotic thrombocytopenic purpura: a case series","volume":"2","author":"Atrash","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1053\/j.ackd.2021.11.006_bib68","series-title":"Genetic sequences may influence clinical progression or clinical presentations of C3 glomerulo-nephropathy [abstract]","author":"Beng","year":"2015"},{"issue":"Suppl 64","key":"10.1053\/j.ackd.2021.11.006_bib69","article-title":"[Genetics of aHUS and transplant recurrence]","volume":"32","author":"Bresin","year":"2015","journal-title":"G Ital Nefrol"},{"issue":"12","key":"10.1053\/j.ackd.2021.11.006_bib70","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1681\/ASN.2018070759","article-title":"Genetic Analysis of 400 patients Refines understanding and implicates a new gene in atypical hemolytic uremic syndrome","volume":"29","author":"Bu","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in pateints with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib72","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00467-010-1734-4","article-title":"Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation","volume":"26","author":"Leroy","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib73","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.kint.2020.06.026","article-title":"Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?","volume":"98","author":"Noris","year":"2020","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib74","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1160\/TH17-06-0404","article-title":"Insights into 3D Structure of ADAMTS13: a Stepping Stone towards novel therapeutic treatment of thrombotic thrombocytopenic purpura","volume":"118","author":"Ercig","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.ackd.2021.11.006_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: Unraveling Ariadne's Thread into the Labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1053\/j.ackd.2021.11.006_bib77","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/IJNRD.S162071","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment","volume":"11","author":"Arman","year":"2018","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1053\/j.ackd.2021.11.006_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","article-title":"Thrombotic microangiopathies of pregnancy: differential diagnosis","volume":"12","author":"Gupta","year":"2018","journal-title":"Pregnancy Hypertens"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/AOG.0000000000003554","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome: a systematic review","volume":"135","author":"Gupta","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1053\/j.ackd.2021.11.006_bib80","doi-asserted-by":"crossref","first-page":"101331","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement dysregulation in glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin Immunol"},{"issue":"2S","key":"10.1053\/j.ackd.2021.11.006_bib81","first-page":"S1059","article-title":"Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome","volume":"226","author":"Burwick","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib82","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2015.02.030","article-title":"The complement system and adverse pregnancy outcomes","volume":"67","author":"Regal","year":"2015","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V32.2.278.278","article-title":"Microangiopathic hemolytic anemia in rats with malignant hypertension","volume":"32","author":"Venkatachalam","year":"1968","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib85","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","article-title":"Clinical features of malignant hypertension with thrombotic microangiopathy","volume":"33","author":"Akimoto","year":"2011","journal-title":"Clin Exp Hypertens"},{"issue":"205","key":"10.1053\/j.ackd.2021.11.006_bib86","article-title":"A case report of thrombotic microangiopathic malignant hypertension","volume":"4","author":"Basturk","year":"2015","journal-title":"J Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","article-title":"Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura","volume":"6","author":"Khanal","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"10.1053\/j.ackd.2021.11.006_bib88","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.2169\/internalmedicine.55.6332","article-title":"Malignant hypertension with thrombotic microangiopathy","volume":"55","author":"Mitaka","year":"2016","journal-title":"Intern Med"},{"issue":"8","key":"10.1053\/j.ackd.2021.11.006_bib89","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells Reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib90","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2021.11.006_bib91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jch.12664","article-title":"Does Anticomplement therapy have a role in the management of malignant hypertension?","volume":"18","author":"Tsai","year":"2016","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.hjh.0000491541.18385.10","article-title":"A patient with malignant hypertension sucsessfully treated with eculizumab and bosentan","volume":"34","author":"Mitchell","year":"2016","journal-title":"J Hypertens"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib93","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/ckj\/sfu116","article-title":"Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI)","volume":"7","author":"Nzerue","year":"2014","journal-title":"Clin Kidney J"},{"issue":"10","key":"10.1053\/j.ackd.2021.11.006_bib94","first-page":"1136","article-title":"Malignant hypertension as a rare cause of thrombotic microangiopathy","volume":"2017","author":"Thind","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib95","first-page":"1055","article-title":"Atypical hemolytic uremic syndrome may present as severe hypertension without hemolysis or thrombocytopenia","volume":"3","author":"Tsai","year":"2016","journal-title":"Austin J Nephrol Hypertens"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2019.11.002","article-title":"Complement and renal thrombotic microangiopathy associated with hypertension and scleroderma","volume":"27","author":"Zuckerman","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2021.11.006_bib97","article-title":"Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"24","key":"10.1053\/j.ackd.2021.11.006_bib98","doi-asserted-by":"crossref","first-page":"e7144","DOI":"10.1097\/MD.0000000000007144","article-title":"Different types of glomerulonephritis associated with the dysregulation of the complement alternative pathway in 2 brothers: a case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib99","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MOT.0b013e3283425509","article-title":"Emerging role of the mannose-binding lectin-dependent pathway of complement activation in clinical organ transplantation","volume":"16","author":"Berger","year":"2011","journal-title":"Curr Opin Organ Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/tmrv.2002.33460","article-title":"Role of complement in graft rejection after organ transplantation","volume":"16","author":"Bos","year":"2002","journal-title":"Transfus Med Rev"},{"key":"10.1053\/j.ackd.2021.11.006_bib101","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2019.02380","article-title":"The role of complement in organ transplantation","volume":"10","author":"Grafals","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.ackd.2021.11.006_bib102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1432-2277.2006.00448.x","article-title":"The role of complement and Toll-like receptors in organ transplantation","volume":"20","author":"Lin","year":"2007","journal-title":"Transpl Int"},{"issue":"9","key":"10.1053\/j.ackd.2021.11.006_bib103","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC transplantation","volume":"99","author":"De Fontbrune FS1","year":"2015","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ackd.2021.11.006_bib104","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13127","article-title":"Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients","volume":"101","author":"Rudoni","year":"2018","journal-title":"Eur J Haematol"},{"issue":"13","key":"10.1053\/j.ackd.2021.11.006_bib105","first-page":"1049","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.ackd.2021.11.006_bib106","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv"},{"issue":"1043","key":"10.1053\/j.ackd.2021.11.006_bib107","article-title":"Effective treatment of thrombotic microangiopathy associated with lupus nephritis with eculizumab: a series of 8 cases","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.ackd.2021.11.006_bib108","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1053\/j.ackd.2021.11.006_bib109","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2021.11.006_bib110","first-page":"649","article-title":"Cancer-associated thrombotic microangiopathy","volume":"10","author":"Govind Babu","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"10.1053\/j.ackd.2021.11.006_bib111","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000507417","article-title":"A case of novel coronavirus disease 19 in a chronic Hemodialysis patient presenting with Gastroenteritis and developing severe pulmonary disease","volume":"51","author":"Ferrey","year":"2020","journal-title":"Am J Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2021.11.006_bib112","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.dld.2020.06.019","article-title":"COVID-19-related thrombotic microangiopathy in a cirrhotic patient","volume":"52","author":"Airoldi","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"1","key":"10.1053\/j.ackd.2021.11.006_bib113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/MNH.0000000000000671","article-title":"Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant","volume":"30","author":"Ferrey","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"15","key":"10.1053\/j.ackd.2021.11.006_bib114","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.kint.2020.05.025","article-title":"Thrombotic microangiopathy in a patient with COVID-19","volume":"98","author":"Jhaveri","year":"2020","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2021.11.006_bib116","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ckj\/sfab024","article-title":"Successful treatment of a COVID-19 patient with thrombotic microangiopathy","volume":"14","author":"Safak","year":"2021","journal-title":"Clin Kidney J"},{"issue":"9","key":"10.1053\/j.ackd.2021.11.006_bib117","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1681\/ASN.2020050699","article-title":"COVID-19-Associated kidney injury: a case series of kidney biopsy findings","volume":"31","author":"Sharma","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib118","doi-asserted-by":"crossref","first-page":"83","DOI":"10.14740\/jh825","article-title":"Thrombotic microangiopathy in a patient with COVID-19 infection and Metastatic Cholangiocarcinoma","volume":"10","author":"Sharma","year":"2021","journal-title":"J Hematol"},{"issue":"11","key":"10.1053\/j.ackd.2021.11.006_bib119","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.it.2020.09.008","article-title":"The complement C5a-C5aR1 GPCR Axis in COVID-19 therapeutics","volume":"41","author":"Woodruff","year":"2020","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1053\/j.ackd.2021.11.006_bib120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0002-9440(10)64189-2","article-title":"Cardiomyopathy is linked to complement activation","volume":"161","author":"Afanasyeva","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.ackd.2021.11.006_bib121","doi-asserted-by":"crossref","first-page":"577487","DOI":"10.1016\/j.jneuroim.2021.577487","article-title":"Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients","volume":"353","author":"Yue","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1053\/j.ackd.2021.11.006_bib122","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/DDDT.S206355","article-title":"Complement system and age-related macular degeneration: drugs and challenges","volume":"13","author":"Wu","year":"2019","journal-title":"Drug Des Devel Ther"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521001488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559521001488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:05:00Z","timestamp":1761548700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559521001488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1548559521001488"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2021.11.006","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathy Syndromes\u2014Common Ground and Distinct Frontiers","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}